Monday, November 14, 2016
- 9:00AM-11:00AM
-
Abstract Number: 1648
Long-Term Clinical, Radiographic and Patient-Reported Outcomes Based on RAPID3 Responses with Tofacitinib at 6 Months
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II- 9:00AM-11:00AM
-
Abstract Number: 1786
Long-Term Evolution of Risk Factors for Atherosclerotic Cardiovascular Events in Systemic Lupus Erythematosus in a Large Case Control Cohort Study
Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life- 9:00AM-11:00AM
-
Abstract Number: 1135
Long-Term Impact of an Enhanced Rheumatology Curriculum for Internal Medicine Residents
Education - Poster- 9:00AM-11:00AM
-
Abstract Number: 1763
Long-Term Impact of Belimumab on Health-Related Quality of Life and Fatigue in Patients with Systemic Lupus Erythematosus Following 7 Years of Treatment Exposure: Impact of Clinical Characteristics over Time
Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life- 9:00AM-11:00AM
-
Abstract Number: 1740
Long-Term Improvements in Physical Function of DMARD-Naive and DMARD/Biologic-Experienced Psoriatic Arthritis Patients Treated with Apremilast: Data from a Large Database of 4 Phase III Clinical Trials
Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis- 9:00AM-11:00AM
-
Abstract Number: 1367
Long-Term Outcomes and Their Predictors in Patients with Juvenile Idiopathic Inflammatory Myopathies of Adult Age: A Referral Population Study
Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster II: Myositis, Systemic Lupus Erythematosus, Sjögren's Syndrome- 9:00AM-11:00AM
-
Abstract Number: 1335
Long–Term Safety and Efficacy of Adalimumab in Patients with Non-Infectious Intermediate, Posterior, or Panuveitis in an Ongoing Open-Label Study
Miscellaneous Rheumatic and Inflammatory Diseases - Poster II- 9:00AM-11:00AM
-
Abstract Number: 1873
Longitudinal Analysis of Modified Rodnan Skin Score in Systemic Sclerosis Using Group-Based Trajectory Modelling
Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster II- 9:00AM-11:00AM
-
Abstract Number: 1554
Longitudinal Trajectories of the Weighted Lansbury Articular Indices and Standard Joint Counts Are Similarly Correlated with Trajectories of Physical Function in Early Inflammatory Arthritis
Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications- 9:00AM-11:00AM
-
Abstract Number: 1791
Loss of Elbow Hyperextension in Females with Early Rheumatologic Disease Was Common in Systemic Lupus Erythematosus and Rheumatoid Arthritis but Rare in Fibromyalgia
Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life- 9:00AM-11:00AM
-
Abstract Number: 1194
Low Body Mass Index and Smoking Are Associated with a Lower Risk of Sarcoidosis: A Population-Based Nested Case-Control Study
Epidemiology and Public Health - Poster II- 9:00AM-11:00AM
-
Abstract Number: 1874
Low Rate of Progression in Cases of Isolated Raynaud’s Phenomenon Screened By Nailfold Videocapillaroscopy and Antinuclear Antibody Status Supports Negative Predictive Value of These Tests
Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster II- 9:00AM-11:00AM
-
Abstract Number: 1558
Lower Expression of a Novel Cytoplasmic Long Noncoding RNA NR_122076 Contributes to Proliferation, Migration and Invasion of Fibroblast-like Synoviocytes from Patients with Rheumatoid Arthritis
Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster II